Yesterday there was not only news from Inflarx, but also a price jump including a new technical buy signal for the NASDAQ-listed share of the Jena biotech company. In the phase II study with vilobelimab in the treatment of vasculitis, an inflammation of the blood vessels, the company was able to complete the patient registration and thus achieve an important milestone in the course of the study. There should be results in the course of the year. According to this news yesterday on the NASDAQ, the share price of Inflarx rose more than 12 percent to $ 5.76 on a closing price basis, with a peak of $ 5.90 during the day.
In terms of charts, buy signals reinforced the effect of yesterday’s news from Inflarx. The company’s share price broke some tight resistance levels between the core zones at $ 5.37 / $ 5.41 and $ 5.48 / $ 5.57. With the exception of a price spike on July 21, 2020, when the Inflarx share climbed to $ 6.20, this zone was the lid on the Jenaer share price for months.